The second breast cancer susceptibility gene, BRCA2, was recently isolated. Breast cancer is highly penetrant in individuals carrying germ-line mutations in this gene. Like BRCA1, it has a large open reading frame that predicts the synthesis of a protein of completely unknown function. Understanding the normal function of BRCA2 and how the loss of this function predisposes towards breast cancer will require a multi-disciplinary approach. This proposal will continue our initial characterization of BRCA2 towards this end.
Four aims are described: 1) Reagents for the study of BRCA2 will be developed which include monoclonal antibodies raised against recombinant fragments of the protein, a full length wild-type cDNA and cDNAs with commonly occurring mutations. Initial characterization of the protein will be performed with these reagents. 2) Expression of BRCA2 will be examined in retrospective cohorts of frozen breast and ovarian cancers and compared to normal specimens from these same organs. Altered expression or subcellular location will be noted and compared to established clinico- pathologic parameters. Methylation status of a CpG island in the promoter will be measured and correlated with gene expression. 3) Since BRCA2 expression is regulated with the cell cycle with a dramatic increase observed at the G1/S boundary, its role in processes mediated at this time will be examined. These include apoptosis, differentiation, and response to DNA damaging agents. 4) The BRCA2 promoter responsible for cell cycle regulation will be isolated and the cis and trans acting elements defined. The initial focus will be on the E2F family of transcription factors which regulate other genes with similar cell cycle profile.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA073802-02S1
Application #
2795905
Study Section
Pathology B Study Section (PTHB)
Program Officer
Lively, Tracy (LUGO)
Project Start
1997-06-11
Project End
2001-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Wang, Wei; Nahta, Rita; Huper, Gudrun et al. (2004) TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. Mol Cancer Res 2:442-52
Lobenhofer, E K; Marks, J R (2000) Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity. J Steroid Biochem Mol Biol 75:20-Nov
Lobenhofer, E K; Huper, G; Iglehart, J D et al. (2000) Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 11:99-110
Davis, P L; Miron, A; Andersen, L M et al. (1999) Isolation and initial characterization of the BRCA2 promoter. Oncogene 18:6000-12